Sheaff Brock Investment Advisors, LLC Spectrum Pharmaceuticals Inc Transaction History

Sheaff Brock Investment Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$0.65 - $1.31 $5,850 - $11,790	-9,000 Reduced 19.07%	38,200 $36,000
Q1 2023 May 01, 2023	BUY	$0.38 - $1.07 $760 - $2,140	2,000 Added 4.42%	47,200 $35,000
Q4 2022 Feb 13, 2023	BUY	$0.32 - $0.52 $2,560 - $4,160	8,000 Added 21.51%	45,200 $16,000
Q3 2022 Nov 03, 2022	BUY	$0.43 - $1.56 $4,730 - $17,160	11,000 Added 41.98%	37,200 $16,000
Q2 2022 Aug 02, 2022	BUY	$0.7 - $1.4 $2,100 - $4,200	3,000 Added 12.93%	26,200 $20,000
Q1 2022 May 16, 2022	BUY	$0.63 - $1.59 $1,260 - $3,180	2,000 Added 9.43%	23,200 $30,000
Q1 2022 May 06, 2022	BUY	$0.63 - $1.59 $2,520 - $6,360	4,000 Added 23.26%	21,200 $27,000
Q4 2021 Jun 02, 2022	BUY	$1.27 - $2.42 $2,540 - $4,840	2,000 Added 13.16%	17,200 $22,000
Q4 2021 Feb 03, 2022	BUY	$1.27 - $2.42 $3,302 - $6,292	2,600 Added 20.63%	15,200 $19,000
Q3 2021 Jun 02, 2022	BUY	$2.15 - $3.82 $5,375 - $9,550	2,500 Added 24.75%	12,600 $27,000
Q3 2021 Nov 03, 2021	BUY	$2.15 - $3.82 $21,715 - $38,582	10,100 New	10,100 $22,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Sheaff Brock Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Sheaff Brock Investment Advisors, LLC with notifications on news.